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UVB Irradiation Increases the Release of SCF from Human
Epidermal Cells
To the Editor:
Stem cell factor (SCF) is a multifunctional growth factor that
is critical for the survival and maturation of melanocytes,
and which also affects dermal mast cell growth, accumu-
lation and degranulation. It is one of the membrane-an-
chored growth factors that are processed to soluble forms
by proteolytic cleavage, and which function both as soluble
and as membrane molecules (Ashman, 1999). Recently,
Hachiya et al (2001) reported that ultraviolet B (UVB) irra-
diation increases membrane-bound SCF content in human
epidermis and in cultured keratinocytes, and they suggest-
ed the participation of this type of SCF in UVB-induced
melanogenesis, in which this molecule would bind to the
c-kit receptor on melanocytes, resulting in persistent c-kit
activation. That study however, did not fully examine the
relationship of soluble type SCF, as they could not detect it.
On the other hand, one report showed that chronic UVB
exposure increases the number of dermal mast cells, ac-
companied by increased epidermal SCF expression in al-
bino hairless mice (Kligman and Murphy, 1996), whereas
another study showed that subcutaneous injection of re-
combinant SCF or transgene expression to produce soluble
SCF in the epidermis causes cutaneous mast cell hyperpl-
asia and cutaneous hyperpigmentation (Grichnik et al, 1995;
Kunisada et al, 1998). These observations led us to spec-
ulate that epidermal SCF also acts as a soluble factor in
UV-exposed skin. Thus, in this study, we examined the
possibility that stimulation of SCF release occurs in UVB-
exposed cultured keratinocytes and in human epidermis.
Normal human epidermal keratinocytes were purchased
from Kurabo (Osaka, Japan) and were cultured in
MCDB153HAA medium (Kyokuto, Tokyo, Japan) supple-
mented with ethanolamine (0.1 mM), phosphoethanolamine
(0.1 mM), hydrocortisone (0.5 nM), epidermal growth factor
(0.1 ng per mL, Sigma, St Louis, Missouri), insulin (5 mg per
mL, Sigma), and bovine pituitary extract (BPE; 4 mL per mL,
Kurabo). At sub-confluence, the cells were transferred to
starvation medium (without BPE) 24 h prior to UVB stimu-
lation, which was carried out twice at a 24-h interval using
FL20SE lamps (Toshiba, Tokyo, Japan). The culture media
were harvested 24 h after the second UVB irradiation and
were analyzed using an ELISA. As shown in Fig 1a, the
amount of SCF in the culture medium was increased by
UVB stimulation in a dose-dependent manner up to 20 mJ
per cm2, and then decreased at a dose of 40 mJ per cm2
with an accompanying reduction of cell viability. Further,
western blot analysis revealed that UVB irradiation caused
an increase of the 31-kDa SCF protein band, which peaked
at a dose of 20 mJ per cm2 (Fig 1b). In addition, the mo-
lecular weight of that band corresponded to the cleaved
form of full-length membrane-bound SCF. These results
show that UVB irradiation at non-cytotoxic doses increases
the release of SCF by cultured human keratinocytes. Our
in vitro findings were further supported by an experiment
using a living skin equivalent (MEL-300, Kurabo), in which
UVB stimulation also resulted in increased SCF content in
the culture medium (data not shown). In a previous study,
performed under conditions that induced a significant re-
duction of cell viability by UVB irradiation, a UVB-induced
upregulation of SCF release could not be detected (Hachiya
Figure1
UVB stimulation increases SCF release from cultured human ker-
atinocytes. (a) Effects of UVB irradiation on SCF release and cell vi-
ability of keratinocytes. The bars and polygonal line show the SCF
content in culture medium and cell viability, respectively. SCF content
was determined using an ELISA (Quantikine, R&D Systems, Minneapo-
lis, Minnesota). Cell viability was measured using an alamarBlue Assay
(Alamar Biosciences, Sacramento, California) 24 h after the second
UVB irradiation. Each value is presented as the mean  SD of three
determinations. po0.01, po0.05 as compared with the control by
Dunnett’s test. (b) Detection of soluble SCF by western blotting. Sam-
ples were concentrated 10-fold using a Centricon YM-10 (Millipore,
Bedford, Massachusetts) and were separated by gel electrophoresis.
Rabbit anti-SCF (Immuno-Biological Laboratories, Gunma, Japan) was
used as a primary antibody.
Abbreviations: SCF, stem cell factor; UP, urticaria pigmentosa; UV,
ultraviolet
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et al, 2001). Therefore, it seems that responses induced by
UVB irradiation at non-cytotoxic levels were not considered
in that study.
Following approval from the Ethical Committee of
Kanebo Basic Research Laboratory, we also administered
UVB irradiation, which was performed with 2 MED of UVB
(0.09–0.12 J per cm2; FL20SE lamps), to the upper-back
area (2.0 cm  2.0 cm) of 10 healthy male Japanese vol-
unteers who gave their written informed consent, after
which analyses of SCF and c-kit expression were per-
formed 3 and 10 days following the irradiation on skin bi-
opsy specimens. Five millimeter-punch biopsies were taken
from each exposed region following the experimental
irradiation. As a control, non-exposed skin areas were al-
so biopsied from all subjects. SCF was detected by
immunohistochemistry throughout the epidermis in intact
skin, as previously reported (Fig 2a: Longley et al, 1993;
Weiss et al, 1995). Three days after the irradiation, cyto-
plasmic staining of SCF was found to be reduced in epi-
dermal keratinocytes, whereas membrane-associated SCF
staining was clearly seen in the epidermal upper spinous
and granular layers (Fig 2b). Thereafter, those levels
returned to nearly normal by day 10 (Fig 2c). Further, a de-
creased expression of c-kit on melanocytes was observed
on day 3 after UVB (Fig 2d–f ).
Changes in epidermal SCF-immunostaining patterns to
reduced cytoplasmic staining and membrane-associated
staining have been reported in lesional urticaria pigmentosa
(UP), a skin disease characterized by dermal accumulations
of mast cells and increased epidermal melanin. Such
changes are considered to result from the altered metab-
olism of SCF, which induces an elevation of soluble SCF
in the skin (Longley et al, 1993; Weiss et al, 1995). On the
other hand, it has been reported that the c-kit receptor is
internalized and degraded after binding its soluble ligands
(Shimizu et al, 1996), and our experiment showed de-
creased c-kit expression on day 3 (Fig 2e). Therefore,
altered SCF immunoreactivity observed on day 3 might be
the consequence of enhanced SCF liberation in the
epidermis.
From reports that serum SCF levels are elevated in
patients with various skin diseases (e.g. atopic dermatitis,
scleroderma) and that those levels recover with clinical im-
provement (Kanbe et al, 2001; Yamamoto et al, 2001), there
is every probability that SCF shedding occurs in cutaneous
tissues. Furthermore, it has been revealed that several pro-
teases are involved in the release of SCF (Pandiella et al,
1992; Gallea-Robache et al, 1997; Longley et al, 1997; He-
issig et al, 2002), and the profiles of some of these enzymes
in the skin are altered by UV exposure (Fisher et al, 1997).
Thus, it seems that UV irradiation of the skin establishes a
condition in which SCF shedding occurs.
In conclusion, SCF release from cultured epidermal cells
was increased by UVB radiation, which also altered the
SCF/c-kit expression pattern in human epidermis. These
results suggest that SCF/c-kit signaling in UV-exposed skin
occurs through soluble SCF, as well as through the mem-
brane-bound form.
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Sun Protection, Vitamin D Deﬁciency, and Management of
Cutaneous Oncology in Organ Transplant Recipients (OTR)
To the Editor:
We have read with great interest the excellent article of
Carucci (2004) who has carried out a comprehensive review
of epidemiology, pathogenesis, and clinical outcome of skin
cancer in organ transplant recipients (OTR) and has given
recommendations for its medical management. We would
like to add to this discussion an important topic that has not
been addressed by John A. Carucci, but that we dermatol-
ogists must be aware of: the fact that strict sun protection
may lead in OTR to the severe health risk of vitamin D de-
ficiency. We know that OTR may develop 25-hydroxyvitamin
D deficiency (Segal et al, 2001), likely at least in part due to
lack of sun exposure. But an epidemiologic association be-
tween vitamin D deficiency and a broad variety of severe
health problems including various types of malignancies
(e.g. colon-, prostate-, and breast cancer) has now been
reported convincingly (Garland et al, 1989; Grant, 2002). It is
now evident that a broad variety of tissues including skin,
prostate, colon, and breast express the enzyme (25-hydro-
xyvitamin D-1a-hydroxylase) to convert 25-hydroxyvitamin
D to its active form, 1,25-dihydroxyvitamin D (Schwartz
et al, 1998; Tangpricha et al, 2001). 1,25-dihydroxyvitamin D
is now not exclusively considered as a calciotropic hormone
but also as a locally produced regulator of different cellular
functions including cellular growth (Schwartz et al, 1998;
Tangpricha et al, 2001). As John Carucci points out, regular
dermatological follow-up must be provided for OTR. In this
context, we would like to strengthen the fact that it is of high
importance to detect and to treat 25-hydroxyvitamin D de-
ficiency in OTR. Recommendations for the oral treatment of
vitamin D deficiency have been reported previously (Ma-
labanan et al, 1998; Vieth, 1999). A single dose of 50,000 IU
vitamin D once a week for 8 wk is efficient and safe. Another
means of guaranteeing vitamin D sufficiency is to give
50,000 IU of vitamin D once a month. We would like to
accentuate the fact that careful monitoring of vitamin D
status and oral substitution in case of vitamin D deficiency
is of high importance for OTR, as we have recommended
previously (Reichrath, 2003, 2004). This will protect OTR
sufficiently against the serious health problems of 25-hy-
droxyvitamin D deficiency without further increasing their
risk of developing squamous cell carcinoma of the skin or
other types of UV-induced skin cancer.
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